Grace Qun Gong

Grace Qun Gong

Auto-generated profile, based on publicly available information

Grace Qun Gong

The National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, 201203, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Nature
Verified
Journal Article
Open access
PDF file
GGGrace Q. Gong
Grace Q. Gong
BBBenoit Bilanges
Benoit Bilanges
BABen Allsop
Ben Allsop
GMGlenn R. Masson
Glenn R. Masson
VRVictoria Roberton
Victoria Roberton
BVBart Vanhaesebroeck
Bart Vanhaesebroeck
Harnessing the potential beneficial effects of kinase signalling through the generation of direct kinase activators remains an underexplored area of drug development1,2,3,4,5. This also applies to the PI3K signalling pathway, which has been extensively targeted by inhibitors for conditions with PI3K overactivation, such as cancer and immune dysregulation. Here we report the discovery of UCL-TRO-1938 (referred to as 1938 hereon), a small-molecule activator of the PI3Kα isoform, a crucial effector of growth factor signalling. 1938 allosterically activates PI3Kα through a distinct mechanism by enhancing multiple steps of the PI3Kα catalytic cycle and causes both local and global conformational changes in the PI3Kα structure. This compound is selective for PI3Kα over other PI3K isoforms and multiple protein and lipid kinases. It transiently activates PI3K signalling in all rodent and human cells tested, resulting in cellular responses such as proliferation and neurite outgrowth. In rodent models, acute treatment with 1938 provides cardioprotection from ischaemia–reperfusion injury and, after local administration, enhances nerve regeneration following nerve crush. This study identifies a chemical tool to directly probe the PI3Kα signalling pathway and a new approach to modulate PI3K activity, widening the therapeutic potential of targeting these enzymes through short-term activation for tissue protection and regeneration. Our findings illustrate the potential of activating kinases for therapeutic benefit, a currently largely untapped area of drug development.

25 October 2024 in Science
Verified
Journal Article
Closed access
MSManojit Mosur Swamynathan
Manojit Mosur Swamynathan
SKShan Kuang
Shan Kuang
KWKaitlin E. Watrud
Kaitlin E. Watrud
MDMary R. Doherty
Mary R. Doherty
CGCharlotte Gineste
Charlotte Gineste
LTLloyd C Trotman
Lloyd C Trotman
Men taking antioxidant vitamin E supplements have increased prostate cancer (PC) risk. However, whether pro-oxidants protect from PC remained unclear. In this work, we show that a pro-oxidant vitamin K precursor [menadione sodium bisulfite (MSB)] suppresses PC progression in mice, killing cells through an oxidative cell death: MSB antagonizes the essential class III phosphatidylinositol (PI) 3-kinase VPS34—the regulator of endosome identity and sorting—through oxidation of key cysteines, pointing to a redox checkpoint in sorting. Testing MSB in a myotubular myopathy model that is driven by loss of MTM1 —the phosphatase antagonist of VPS34—we show that dietary MSB improved muscle histology and function and extended life span. These findings enhance our understanding of pro-oxidant selectivity and show how definition of the pathways they impinge on can give rise to unexpected therapeutic opportunities.

1 September 2018 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
RBRajesh Basnet
Rajesh Basnet
GGGrace Qun Gong
Grace Qun Gong
CLChenyao Li
Chenyao Li
MWMing-Wei Wang
Ming-Wei Wang
The serum and glucocorticoid inducible protein kinase (SGK) family members share similar structure, substrate specificity and function with AKT and signal downstream of the phosphatidylinositol 3-kinase (PI3K) signalling pathway. They regulate a range of fundamental cellular processes such as cell proliferation and survival, thereby playing an important role in cancer development. This perspective intends to give an overview on the involvement of SGKs (particularly SGK3) in cancer progression, and compares the actions of SGK3 and AKT in cell cycle regulation, oncogenic signalling, and the potential as a therapeutic target for cancer.

1 March 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SHSamantha D. Heitz
Samantha D. Heitz
DHDavid J. Hamelin
David J. Hamelin
RHReece M. Hoffmann
Reece M. Hoffmann
NGNili Greenberg
Nili Greenberg
GSGilbert Salloum
Gilbert Salloum
JBJonathan M. Backer
Jonathan M. Backer
Phosphoinositide 3-kinase β (PI3Kβ) is regulated by receptor tyrosine kinases (RTKs), G protein–coupled receptors (GPCRs), and small GTPases such as Rac1 and Rab5. Our lab previously identified two residues (Gln-596 and Ile-597) in the helical domain of the catalytic subunit (p110β) of PI3Kβ whose mutation disrupts binding to Rab5. To better define the Rab5–p110β interface, we performed alanine-scanning mutagenesis and analyzed Rab5 binding with an in vitro pulldown assay with GST-Rab5GTP. Of the 35 p110β helical domain mutants assayed, 11 disrupted binding to Rab5 without affecting Rac1 binding, basal lipid kinase activity, or Gβγ-stimulated kinase activity. These mutants defined the Rab5-binding interface within p110β as consisting of two perpendicular α-helices in the helical domain that are adjacent to the initially identified Gln-596 and Ile-597 residues. Analysis of the Rab5–PI3Kβ interaction by hydrogen-deuterium exchange MS identified p110β peptides that overlap with these helices; no interactions were detected between Rab5 and other regions of p110β or p85α. Similarly, the binding of Rab5 to isolated p85α could not be detected, and mutations in the Ras-binding domain (RBD) of p110β had no effect on Rab5 binding. Whereas soluble Rab5 did not affect PI3Kβ activity in vitro, the interaction of these two proteins was critical for chemotaxis, invasion, and gelatin degradation by breast cancer cells. Our results define a single, discrete Rab5-binding site in the p110β helical domain and may be useful for generating inhibitors to better define the physiological role of Rab5–PI3Kβ coupling in vivo.

23 July 2018 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
GGGrace Qun Gong
Grace Qun Gong
KWKe Wang
Ke Wang
XDXin-Chuan Dai
Xin-Chuan Dai
YZYan Zhou
Yan Zhou
RBRajesh Basnet
Rajesh Basnet
MWMing-Wei Wang
Ming-Wei Wang

10 July 2018 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
JWJia Wang
Jia Wang
GGGrace Qun Gong
Grace Qun Gong
YZYan Zhou
Yan Zhou
WLWoo-Jeong Lee
Woo-Jeong Lee
CBChristina Maree Buchanan
Christina Maree Buchanan
MWMing-Wei Wang
Ming-Wei Wang